Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2019 1
2020 11
2021 23
2022 23
2023 12
2024 10
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis.
Manabe T, Kambayashi D, Akatsu H, Kudo K. Manabe T, et al. BMC Infect Dis. 2021 May 27;21(1):489. doi: 10.1186/s12879-021-06164-x. BMC Infect Dis. 2021. PMID: 34044777 Free PMC article.
BACKGROUND: Favipiravir possesses high utility for treating patients with COVID-19. However, research examining the efficacy and safety of favipiravir for patients with COVID-19 is limited. ...CONCLUSIONS: Favipiravir induces viral clearance by 7 days and con …
BACKGROUND: Favipiravir possesses high utility for treating patients with COVID-19. However, research examining the efficacy and safe …
Effectiveness of favipiravir in COVID-19: a live systematic review.
Özlüşen B, Kozan Ş, Akcan RE, Kalender M, Yaprak D, Peltek İB, Keske Ş, Gönen M, Ergönül Ö. Özlüşen B, et al. Eur J Clin Microbiol Infect Dis. 2021 Dec;40(12):2575-2583. doi: 10.1007/s10096-021-04307-1. Epub 2021 Aug 4. Eur J Clin Microbiol Infect Dis. 2021. PMID: 34347191 Free PMC article.
We performed a systematic review and meta-analysis for the effectiveness of Favipiravir on the fatality and the requirement of mechanical ventilation for the treatment of moderate to severe COVID-19 patients. ...Until June 1, 2021, we searched PubMed, bioRxiv, medRxiv, Cli …
We performed a systematic review and meta-analysis for the effectiveness of Favipiravir on the fatality and the requirement of mechan …
Favipiravir-based treatment for outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.
Lan SH, Lai CC, Chang SP, Lu LC, Hung SH, Lin WT. Lan SH, et al. Expert Rev Clin Pharmacol. 2022 Jun;15(6):759-766. doi: 10.1080/17512433.2022.2078701. Epub 2022 May 30. Expert Rev Clin Pharmacol. 2022. PMID: 35579014
Only RCTs that compared the clinical efficacy and safety of favipiravir -based antiviral regimens (study group) with other alternative treatments or placebos (control group) in patients with COVID-19 were included. ...CONCLUSIONS: Except the clinical improvement rate withi …
Only RCTs that compared the clinical efficacy and safety of favipiravir -based antiviral regimens (study group) with other alternativ …
Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis.
Shrestha DB, Budhathoki P, Khadka S, Shah PB, Pokharel N, Rashmi P. Shrestha DB, et al. Virol J. 2020 Sep 24;17(1):141. doi: 10.1186/s12985-020-01412-z. Virol J. 2020. PMID: 32972430 Free PMC article.
BACKGROUND: The COVID-19 causing coronavirus is an enveloped RNA virus that utilizes an enzyme RNA dependent RNA polymerase for its replication. Favipiravir (FVP) triphosphate, a purine nucleoside analog, inhibits that enzyme. We have conducted this systematic review and m …
BACKGROUND: The COVID-19 causing coronavirus is an enveloped RNA virus that utilizes an enzyme RNA dependent RNA polymerase for its replicat …
The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.
Hassanipour S, Arab-Zozani M, Amani B, Heidarzad F, Fathalipour M, Martinez-de-Hoyo R. Hassanipour S, et al. Sci Rep. 2021 May 26;11(1):11022. doi: 10.1038/s41598-021-90551-6. Sci Rep. 2021. PMID: 34040117 Free PMC article.
A number of already approved and marketed drugs are being tested for repurposing, including Favipiravir. We aim to investigate the efficacy and safety of Favipiravir in treatment of COVID-19 patients through a systematic review and meta-analysis. ...Requiring supple …
A number of already approved and marketed drugs are being tested for repurposing, including Favipiravir. We aim to investigate the ef …
A systematic review and Bayesian network meta-analysis for comparative safety assessment of favipiravir interventions in hospitalized COVID-19 patients.
Yang K, Zeng J, Dai W, Chen M, Yang F. Yang K, et al. J Infect Dev Ctries. 2022 Sep 30;16(9):1406-1412. doi: 10.3855/jidc.16083. J Infect Dev Ctries. 2022. PMID: 36223614 Free article.
There is still a lack of evidence for direct comparison of favipiravir therapy. Network meta-analysis (NMA), may incorporate direct and indirect comparisons in a pooled computation while depending on strong assumptions and premises. ...We have also concluded that the safet …
There is still a lack of evidence for direct comparison of favipiravir therapy. Network meta-analysis (NMA), may incorporate direct a …
The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies.
Hung DT, Ghula S, Aziz JMA, Makram AM, Tawfik GM, Abozaid AA, Pancharatnam RA, Ibrahim AM, Shabouk MB, Turnage M, Nakhare S, Karmally Z, Kouz B, Le TN, Alhijazeen S, Phuong NQ, Ads AM, Abdelaal AH, Nam NH, Iiyama T, Kita K, Hirayama K, Huy NT. Hung DT, et al. Int J Infect Dis. 2022 Jul;120:217-227. doi: 10.1016/j.ijid.2022.04.035. Epub 2022 Apr 22. Int J Infect Dis. 2022. PMID: 35470021 Free PMC article.
OBJECTIVES: This study aimed to evaluate the efficacy and adverse events of favipiravir in patients with COVID-19. METHODS: Our protocol was registered on PROSPERO (CRD42020206305). ...Pregnant, lactating women, and patients with a history of hyperuricemia should avoid usi …
OBJECTIVES: This study aimed to evaluate the efficacy and adverse events of favipiravir in patients with COVID-19. METHODS: Our proto …
Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care.
Shah PL, Orton CM, Grinsztejn B, Donaldson GC, Crabtree Ramírez B, Tonkin J, Santos BR, Cardoso SW, Ritchie AI, Conway F, Riberio MPD, Wiseman DJ, Tana A, Vijayakumar B, Caneja C, Leaper C, Mann B, Samson A, Bhavsar PK, Boffito M, Johnson MR, Pozniak A, Pelly M; PIONEER trial group. Shah PL, et al. Lancet Respir Med. 2023 May;11(5):415-424. doi: 10.1016/S2213-2600(22)00412-X. Epub 2022 Dec 14. Lancet Respir Med. 2023. PMID: 36528039 Free PMC article. Clinical Trial.
We aimed to evaluate the safety and efficacy of oral favipiravir in patients hospitalised with COVID-19. METHODS: We conducted a multicentre, open-label, randomised controlled trial of oral favipiravir in adult patients who were newly admitted to hospital with prove …
We aimed to evaluate the safety and efficacy of oral favipiravir in patients hospitalised with COVID-19. METHODS: We conducted a mult …
Favipiravir Treatment of Uncomplicated Influenza in Adults: Results of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials.
Hayden FG, Lenk RP, Stonis L, Oldham-Creamer C, Kang LL, Epstein C. Hayden FG, et al. J Infect Dis. 2022 Nov 11;226(10):1790-1799. doi: 10.1093/infdis/jiac135. J Infect Dis. 2022. PMID: 35639525 Free PMC article. Clinical Trial.
BACKGROUND: We conducted double-blind, placebo-controlled trials assessing the efficacy and tolerability of favipiravir in acute influenza. METHODS: Otherwise healthy adults with influenza-like symptoms and fever of 48 hours were randomized to favipiravir (1800 mg t …
BACKGROUND: We conducted double-blind, placebo-controlled trials assessing the efficacy and tolerability of favipiravir in acute infl …
71 results